Growth Metrics

Collegium Pharmaceutical (COLL) Liabilities and Shareholders Equity (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Liabilities and Shareholders Equity data on record, last reported at $1.6 billion in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 1.7% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $4.8 billion, down 11.62%, while the annual FY2024 figure was $1.7 billion, 45.51% up from the prior year.
  • Liabilities and Shareholders Equity reached $1.6 billion in Q3 2025 per COLL's latest filing, up from $1.6 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.7 billion in Q4 2024 and bottomed at $646.1 million in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 92.88% in 2022, then decreased 13.22% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $692.1 million in 2021, then skyrocketed by 69.65% to $1.2 billion in 2022, then decreased by 2.63% to $1.1 billion in 2023, then surged by 45.51% to $1.7 billion in 2024, then decreased by 3.38% to $1.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.6 billion in Q3 2025, $1.6 billion in Q2 2025, and $1.6 billion in Q1 2025.